#Belgium #Sjögren's Disease #AbolerIS Pharma #Gosselies #CD45RC

AbolerIS Pharma Unveils Insights on CD45RC in Sjögren's Disease

AbolerIS Pharma, a pioneering name in the realm of biopharmaceuticals, recently presented groundbreaking developments regarding CD45RC, at the EULAR 2026 Congress in London. This gathering, renowned for spotlighting vital rheumatology research, provided the perfect backdrop for AbolerIS to showcase their findings which reveal CD45RC's potential as a critical player in Sjögren's disease (SjD).

AbolerIS is focused on addressing autoimmune and inflammatory diseases with its development of innovative immunomodulatory antibodies. Among these, the company's efforts revolve around targeting CD45RC, recognized as a significant modulator of antigen receptor signaling in T and B cells. The results shared at EULAR highlighted that CD45RC is significantly present within lymphocytic infiltrates in salivary glands affected by SjD.

Significant Findings

Key highlights of the research presented include:

• - Correlation with Lymphocytic Infiltration: The expression of CD45RC was found to be closely tied to the degree of lymphocytic infiltration observed within patient salivary glands. This means that higher levels of CD45RC expression could indicate more severe disease involvement.
• - Localization: It was also noted that CD45RC specifically localizes to areas affected by the disease, making it a potential early biomarker for identifying Sjögren's disease in its nascent stages.
• - Broad Applicability: Notably, the findings regarding CD45RC expression were valid regardless of anti-SSA antibody status, widening its applicability across different patient groups.

Dr. Ronald Van Brempt, CMO of AbolerIS, expressed satisfaction in the data presented, emphasizing the role of CD45RC as a critical regulator of harmful immune responses in autoimmune disorders. He pointed out that early detection of CD45RC might allow therapeutic interventions before the disease reaches more advanced stages, where treatment options are often limited.

Professor Dirk Elewaut from Ghent University Hospital remarked on the compelling connection between CD45RC expression levels and lymphocytic infiltration, stating, "These findings not only enhance our comprehension of Sjögren's disease biology but also underscore the potential of CD45RC as a biomarker for identifying and stratifying patients."

The significance of these discoveries is underscored by AbolerIS's development of their lead antibody, ABO21009, which is currently in a Phase I clinical trial. This antibody aims to evaluate safety and pharmacodynamics in both healthy volunteers and patients with rheumatoid arthritis.

Implications for the Future

The implications of the findings presented at EULAR are profound, potentially paving the way for new therapeutic strategies targeting CD45RC. Given the autoimmune nature of Sjögren's disease, a condition that currently lacks sufficient treatment avenues, the role of CD45RC as both a therapeutic target and biomarker is pivotal. This could lead not only to more effective management of SjD but also improve the quality of life for those grappling with this condition.

AbolerIS Pharma continues to demonstrate commitment to this cause, pushing the boundaries of research and drug development. With CD45RC identifying itself as a prospective target, the future of Sjögren's disease treatment may be on the brink of a transformation, offering hope to many patients around the globe.

Conclusion

As understanding of Sjögren's disease evolves, AbolerIS Pharma remains at the vanguard of biopharmaceutical development, fostering innovative solutions that aim to redefine treatment strategies in autoimmune disorders. The intriguing findings related to CD45RC herald a new chapter in addressing Sjögren's disease, one which promises to enhance patient outcomes significantly.

For more detailed insights and news on their progress, visit AbolerIS Pharma's website.